Overview
A. Pharmakon Advisors, LP (also referred to as “we”, the “Firm” and “Pharmakon”),
founded in 2009, is an investment services firm specializing in investment
management for private funds that are deemed to be pooled investment vehicles
and their respective feeder funds (collectively the “Funds”). Pharmakon also
provides certain investment advisory services to a public limited company in the
UK (the “UK Trust”). Throughout this Brochure, “clients”, when used respect to
the Firm, refer to the Funds and the UK Trust. The principal owners of Pharmakon
are Pedro Gonzalez de Cosio and Pablo Legorreta.
B. Pharmakon specializes in offering investment management services to its clients,
which are comprised of the Funds and the UK Trust. In providing our advisory
services to our clients, we focus on acquiring high yielding debt securities and
instruments, including senior secured debt and capped return royalties with short
average lives, which are securitized
or collateralized by the assets and products of
life sciences companies and the royalty payments on one or more life sciences
products, as applicable, which we believe will have good sales visibility during the
expected life of such securities or instruments.
C. Our Firm tailors our advisory services to the individual needs and specified
investment mandates of our clients; however, the Firm does not tailor advisory
services to the underlying individual investors in the clients. We adhere to the
investment strategy set forth in our clients’ confidential private placement
memoranda, investment management agreements, prospectus and other governing
documents as applicable.
D. We do not participate in wrap fee programs.
The amount of client assets that we manage, as of December 31, 2023 is
approximately $3,128,821,083, all of which are managed on a discretionary basis.
We manage the Funds and the UK Trust on a discretionary basis.